Clinical Trials · NCT02624973
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Haukeland University Hospital
- Enrollment
- 200
- Start date
- Apr 2016
- Locations
- 7 sites, Norway
- Primary endpoint
- Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing before starting neoadjuvant therapy.